AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

EyePoint Pharmaceuticals, Inc. Director's Dealing 2021

Jan 14, 2021

32254_dirs_2021-01-14_0bc620df-65ab-4387-9f96-e28bd915b984.zip

Director's Dealing

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2020-12-31

Reporting Person: OcuMension Therapeutics (N/A)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock, $0.001 par value	3010722	Direct